Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Rae

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Clinical Pharmacology and Therapeutics|September 10, 2010
Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated resultsD F Hayes, T C Skaar, J M Rae, et al.
Breast Cancer Research and Treatment|July 22, 2017
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based studyD L Hertz, K M Kidwell, S G Hilsenbeck, et al.
British Journal of Cancer|December 3, 2009
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapyN L Henry, A Nguyen, F Azzouz, et al.
The Pharmacogenomics Journal|August 24, 2016
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancerD L Hertz, K M Kidwell, N J Seewald, et al.
The Pharmacogenomics Journal|May 8, 2009
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsJ M Rae, M J Sikora, N L Henry, et al.
British Journal of Cancer|October 3, 2013
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effectsN L Henry, H-P Chan, J Dantzer, et al.
Molecular Endocrinology (Baltimore, Md.)|December 17, 2011
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in boneR J Hartmaier, A S Richter, R M Gillihan, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Clinical Pharmacology and Therapeutics|September 10, 2010
Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated resultsD F Hayes, T C Skaar, J M Rae, et al.
Breast Cancer Research and Treatment|July 22, 2017
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based studyD L Hertz, K M Kidwell, S G Hilsenbeck, et al.
British Journal of Cancer|December 3, 2009
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapyN L Henry, A Nguyen, F Azzouz, et al.
The Pharmacogenomics Journal|August 24, 2016
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancerD L Hertz, K M Kidwell, N J Seewald, et al.
The Pharmacogenomics Journal|May 8, 2009
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsJ M Rae, M J Sikora, N L Henry, et al.
British Journal of Cancer|October 3, 2013
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effectsN L Henry, H-P Chan, J Dantzer, et al.
Molecular Endocrinology (Baltimore, Md.)|December 17, 2011
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in boneR J Hartmaier, A S Richter, R M Gillihan, et al.
Pageof 2